Effects of antihyperglycemics on endothelial progenitor cells.
10.3785/j.issn.1008-9292.2020.10.13
- Author:
Xue HAN
1
;
Guojun JIANG
2
;
Qiaojuan SHI
1
Author Information
1. Laboratory Animal Center, Hangzhou Medical College, Hangzhou 310015, China.
2. Department of Pharmacy, Zhejiang Xiaoshan Hospital, Hangzhou 311200, China.
- Publication Type:Journal Article
- Keywords:
Antihyperglycemics;
Diabetes mellitus;
Endothelial progenitor cells;
Oxidative stress;
Review;
Telomerase
- MeSH:
Cell Movement/drug effects*;
Cells, Cultured;
Endothelial Progenitor Cells/drug effects*;
Humans;
Hypoglycemic Agents/pharmacology*;
Signal Transduction/drug effects*
- From:
Journal of Zhejiang University. Medical sciences
2020;49(5):629-636
- CountryChina
- Language:Chinese
-
Abstract:
Endothelial progenitor cells (EPCs) play an important role in diabetic vascular complications. A large number of studies have revealed that some clinical antihyperglycemics can improve the complications of diabetes by regulating the function of EPCs. Metformin can improve EPCs function in diabetic patients by regulating oxidative stress level or downstream signaling pathway of adenosine monophosphate activated protein kinase; Pioglitazone can delay the aging of EPCs by regulating telomerase activity; acarbose, sitagliptin and insulin can promote the proliferation, migration and adhesion of EPCs. In addition to lowering blood glucose, the effects of antihyperglycemics on EPCs may also be one of the mechanisms to improve the complications of diabetes. This article reviews the research progress on the regulation of EPC proliferation and function by antihyperglycemics.
